CellTraffix Researchers Refine System for Cell Capture Print E-mail
Study Reveals Implications for Stem Cell and Cancer Diagnostics and Treatment

Rochester, NY, October 31, 2007 – CellTraffix researchers have moved closer to a working model of a new device to selectively isolate and target cells such as stem cells or cancer cells from adult bone marrow or the blood stream.  These findings were reported in an article entitled, Investigating the Feasibility of Stem Cell Enrichment Mediated by Immobilized Selectins, in the October 31, 2007 issue of BIOTECHNOLOGY PROGRESS (http://pubs.acs.org/journals/bipret/index.html free article, no subscription required).  Utilizing small diameter tubes coated on the inside with selectin, a protein to which the targeted cells adhere, this technique would represent a significant advance over current cell collection methods that are more time consuming and often have adverse effects on the target cell population.

“Through this work, we have gained a deeper understanding of the engineering involved to build a highly effective system for enriching stem cells,” said Dr. Michael King, Associate Professor, Biomedical Engineering and Chemical Engineering, at the University of Rochester, whose laboratory did the work.

“The experiments carried out in this comprehensive study significantly advance our progress in developing commercial devices that could be used to isolate adult stem cells for research or regenerative medicine, or certain cancer cells such as leukemia and metastasized colorectal and prostate cancers, in the bloodstream,” said Thomas Fitzgerald, CEO of CellTraffix.  The Company is commercializing a range of medical devices utilizing the research done by Dr. King and his team.

Stem cell therapies utilizing hematopoietic stem and progenitor cells (HSPCs) are used to treat various diseases of the blood and bone marrow, including leukemia, lymphoma, and sickle cell disease.  Enrichment of these precious cells has the potential to reduce the risk of graft vs. host disease and cancer metastasis.  Today, such techniques rely on antibodies to detect and separate the HSPCs, which can result in low levels of cell recovery and require extended processing time.  CellTraffix researchers propose a new method for isolating HSPCs that is faster and results in a higher yield, which could also be used to isolate and remove cancer cells circulating in the body, as certain metastatic and blood cancer cells are also responsive to the same proteins.

About the Study

In a series of experiments, researchers ran a variety of tests using both bone marrow and acute myeloid leukemia cells in selectin-coated flow chambers to determine which selectins (P-, E-, or L-Selectins) were most effective at capturing specific cells under varying circumstances, such as device length and flow rate.

In most cases, optimum separation was achieved in less than 10 minutes with a five-fold increase of cell purity. 

About CellTraffix

CellTraffix is a medical technology company that develops devices and research tools to fight cancer and enhance the collection and use of adult stem cells.  These devices employ CellTraffix patented technology and unique understanding of the mechanics of cellular flow and cell trafficking in the blood stream to develop a range of proprietary medical devices to address a number of unmet medical needs relating to cancer, adult stem cells, and immune cells.
 
CellTraffix has established strategic relationships with the University of Rochester as well as MIT to advance the Company’s core technologies.

Company Contact:
Thomas Fitzgerald
President and CEO
(585) 267-4840

Media Relations:
Deanne Eagle
Cameron Associates
(212) 554-5463
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it